OTCMKTS:CDXI

Cardax Competitors

$2.00
-0.10 (-4.76 %)
(As of 04/14/2021 01:30 PM ET)
Add
Compare
Today's Range
$2.00
Now: $2.00
$2.00
50-Day Range
$1.78
MA: $2.15
$3.00
52-Week Range
$1.15
Now: $2.00
$15.00
Volume166 shs
Average Volume476 shs
Market Capitalization$1.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35

Competitors

Cardax (OTCMKTS:CDXI) Vs. WCUI, KAYS, ISCO, IPCIF, BCTXF, and FWDG

Should you be buying CDXI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cardax, including Wellness Center USA (WCUI), Kaya (KAYS), International Stem Cell (ISCO), Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), and FutureWorld (FWDG).

Cardax (OTCMKTS:CDXI) and Wellness Center USA (OTCMKTS:WCUI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardax and Wellness Center USA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardax0000N/A
Wellness Center USA0000N/A

Insider & Institutional Ownership

8.7% of Cardax shares are held by institutional investors. Comparatively, 0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cardax and Wellness Center USA's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardax$710,000.002.24$-5,090,000.00N/AN/A
Wellness Center USA$30,000.00228.21$-2,390,000.00N/AN/A

Wellness Center USA has lower revenue, but higher earnings than Cardax.

Risk and Volatility

Cardax has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Wellness Center USA has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares Cardax and Wellness Center USA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardax-891.77%N/A-297.64%
Wellness Center USAN/AN/A-1,809.19%

Cardax (OTCMKTS:CDXI) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardax and Kaya, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardax0000N/A
Kaya01002.00

Insider & Institutional Ownership

8.7% of Cardax shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cardax and Kaya's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardax$710,000.002.24$-5,090,000.00N/AN/A
Kaya$1.01 million6.71$7.80 millionN/AN/A

Kaya has higher revenue and earnings than Cardax.

Risk and Volatility

Cardax has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Profitability

This table compares Cardax and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardax-891.77%N/A-297.64%
Kaya-1,558.07%N/A-586.93%

Summary

Cardax beats Kaya on 4 of the 7 factors compared between the two stocks.

Cardax (OTCMKTS:CDXI) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cardax and International Stem Cell, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardax0000N/A
International Stem Cell0000N/A

Valuation and Earnings

This table compares Cardax and International Stem Cell's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardax$710,000.002.24$-5,090,000.00N/AN/A
International Stem Cell$9.47 million0.57$-4,260,000.00N/AN/A

International Stem Cell has higher revenue and earnings than Cardax.

Profitability

This table compares Cardax and International Stem Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardax-891.77%N/A-297.64%
International Stem Cell-55.56%N/A-72.21%

Insider & Institutional Ownership

8.7% of Cardax shares are held by institutional investors. 81.7% of International Stem Cell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Cardax has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Summary

International Stem Cell beats Cardax on 5 of the 8 factors compared between the two stocks.

Intellipharmaceutics International (OTCMKTS:IPCIF) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Intellipharmaceutics International and Cardax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
Cardax0000N/A

Earnings and Valuation

This table compares Intellipharmaceutics International and Cardax's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.57$-8,090,000.00N/AN/A
Cardax$710,000.002.24$-5,090,000.00N/AN/A

Cardax has lower revenue, but higher earnings than Intellipharmaceutics International.

Profitability

This table compares Intellipharmaceutics International and Cardax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-81.71%
Cardax-891.77%N/A-297.64%

Insider & Institutional Ownership

8.7% of Cardax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Intellipharmaceutics International has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Cardax has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.

Summary

Intellipharmaceutics International beats Cardax on 4 of the 7 factors compared between the two stocks.

BriaCell Therapeutics (OTCMKTS:BCTXF) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

0.1% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cardax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares BriaCell Therapeutics and Cardax's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
Cardax$710,000.002.24$-5,090,000.00N/AN/A

BriaCell Therapeutics has higher earnings, but lower revenue than Cardax.

Analyst Recommendations

This is a breakdown of recent ratings for BriaCell Therapeutics and Cardax, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
Cardax0000N/A

Profitability

This table compares BriaCell Therapeutics and Cardax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
Cardax-891.77%N/A-297.64%

Volatility & Risk

BriaCell Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Cardax has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.

Summary

Cardax beats BriaCell Therapeutics on 4 of the 6 factors compared between the two stocks.

FutureWorld (OTCMKTS:FWDG) and Cardax (OTCMKTS:CDXI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

8.7% of Cardax shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares FutureWorld and Cardax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FutureWorldN/AN/AN/AN/AN/A
Cardax$710,000.002.24$-5,090,000.00N/AN/A

FutureWorld has higher earnings, but lower revenue than Cardax.

Analyst Ratings

This is a summary of recent recommendations and price targets for FutureWorld and Cardax, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
FutureWorld0000N/A
Cardax0000N/A

Profitability

This table compares FutureWorld and Cardax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
FutureWorldN/AN/AN/A
Cardax-891.77%N/A-297.64%

Risk and Volatility

FutureWorld has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Cardax has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.

Summary

Cardax beats FutureWorld on 3 of the 5 factors compared between the two stocks.


Cardax Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06-6.7%$6.39 million$30,000.000.00Gap Down
KAYS
Kaya
0.7$0.47-8.1%$6.23 million$1.01 million0.00Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72-4.2%$5.65 million$9.47 million0.00
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23-4.8%$5.19 million$3.48 million-1.92News Coverage
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-16.7%$4.56 millionN/A0.00Gap Down
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11-4.3%$4.49 million$3.65 million0.00Decrease in Short Interest
AMBS
Amarantus BioScience
0.0$0.01-1.8%$4.13 millionN/A0.00Increase in Short Interest
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
RSPI
RespireRx Pharmaceuticals
0.5$0.04-5.6%$3.00 millionN/A-0.09
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17-15.2%$2.94 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Down
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
NSPX
Inspyr Therapeutics
0.5$0.02-1.3%$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-0.0%$2.16 million$20,000.00-0.97
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48-6.2%$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09-0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-21.6%$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-5.9%$1.69 millionN/A0.00
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-0.0%$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04-19.7%$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02-10.4%$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.8%$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03-0.0%$965,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01-12.9%$928,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08-0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-125.0%$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02-36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00-20.0%$678,000.00N/A0.00Increase in Short Interest
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15-1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17-0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07-0.0%$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00News Coverage
Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-0.0%$319,000.00N/A0.00Increase in Short Interest
Gap Down
PZRXQ
PhaseRx
0.2$0.03-0.0%$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09-5.9%$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02-0.0%$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-13.2%$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.